Cascadian Therapeutics Inc. (Nasdaq: CASC) will be acquired by Seattle Genetics Inc. (Nasdaq: SGEN) for a premium of approximately $614 million in cash. Shares of Cascadian Therapeutics surged $4.16 to close at $10.06 while Seattle Genetics stock tumbled $2.91 to close at $52.30.
Seattle Genetics to buy Cascadian Therapeutics
January 31, 2018 at 16:14 PM EST